+

WO1998002534A3 - Animal transgenique dont l'expression des recepteurs aux opiaces est modifiee - Google Patents

Animal transgenique dont l'expression des recepteurs aux opiaces est modifiee Download PDF

Info

Publication number
WO1998002534A3
WO1998002534A3 PCT/FR1997/001282 FR9701282W WO9802534A3 WO 1998002534 A3 WO1998002534 A3 WO 1998002534A3 FR 9701282 W FR9701282 W FR 9701282W WO 9802534 A3 WO9802534 A3 WO 9802534A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
whose expression
opiate receptors
transgenic animal
animal whose
Prior art date
Application number
PCT/FR1997/001282
Other languages
English (en)
Other versions
WO1998002534A2 (fr
Inventor
Brigitte Lina Kieffer
Hans W D Matthes
Frederic Herve Simonin
Andree Dierich
Marianne Lemeur
Original Assignee
Centre Nat Rech Scient
Brigitte Lina Kieffer
Hans W D Matthes
Frederic Herve Simonin
Andree Dierich
Marianne Lemeur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Brigitte Lina Kieffer, Hans W D Matthes, Frederic Herve Simonin, Andree Dierich, Marianne Lemeur filed Critical Centre Nat Rech Scient
Priority to US09/214,904 priority Critical patent/US6632977B2/en
Publication of WO1998002534A2 publication Critical patent/WO1998002534A2/fr
Publication of WO1998002534A3 publication Critical patent/WO1998002534A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne l'utilisation d'un animal mammifère transgénique non humain dont l'expression du gène codant pour un récepteur aux opiacés est modifiée, notamment dans les tissus nerveux par rapport à une expression normale, notamment dans les tissus nerveux, notamment dans les tissus nerveux, pour la détermination d'un médicament actif sur les pathologies impliquant les récepteurs aux opiacés, notamment les douleurs sévères aigües ou chroniques, la toxicomanie, ou la prévention ou le traitement des rejets de greffe.
PCT/FR1997/001282 1996-07-15 1997-07-11 Animal transgenique dont l'expression des recepteurs aux opiaces est modifiee WO1998002534A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/214,904 US6632977B2 (en) 1996-07-15 1997-07-11 Transgenic animal whose expression of the opiate receptors is modified

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9608810A FR2750825B1 (fr) 1996-07-15 1996-07-15 Animal transgenique non humain dans lequel l'expression de l'un au moins des genes codant pour les recepteurs aux opiaces est modifiee
FR96/08810 1996-07-15

Publications (2)

Publication Number Publication Date
WO1998002534A2 WO1998002534A2 (fr) 1998-01-22
WO1998002534A3 true WO1998002534A3 (fr) 1998-02-26

Family

ID=9494043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/001282 WO1998002534A2 (fr) 1996-07-15 1997-07-11 Animal transgenique dont l'expression des recepteurs aux opiaces est modifiee

Country Status (3)

Country Link
US (1) US6632977B2 (fr)
FR (1) FR2750825B1 (fr)
WO (1) WO1998002534A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US7214534B2 (en) 2002-06-18 2007-05-08 Regents Of The University Of Minnesota Isolated nucleic acid molecules encoding mutant μ opioid receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021309A1 (fr) * 1992-04-10 1993-10-28 Duz Partnership Sequences d'oligonucleotides et animaux transgeniques transfectes avec celles-ci et presentant une sensibilite reduite aux analgesiques narcotiques
WO1995007983A1 (fr) * 1993-09-13 1995-03-23 Indiana University Foundation Recepteur mu humain d'opioides
WO1996001898A1 (fr) * 1994-07-11 1996-01-25 Universite Louis Pasteur Recepteur opioide kappa humain, acides nucleiques et utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021309A1 (fr) * 1992-04-10 1993-10-28 Duz Partnership Sequences d'oligonucleotides et animaux transgeniques transfectes avec celles-ci et presentant une sensibilite reduite aux analgesiques narcotiques
WO1995007983A1 (fr) * 1993-09-13 1995-03-23 Indiana University Foundation Recepteur mu humain d'opioides
WO1996001898A1 (fr) * 1994-07-11 1996-01-25 Universite Louis Pasteur Recepteur opioide kappa humain, acides nucleiques et utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTHES, H. ET AL.: "Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene", NATURE, vol. 383, no. 6603, 31 October 1996 (1996-10-31), LONDON GB, pages 819 - 823, XP000613442 *

Also Published As

Publication number Publication date
FR2750825A1 (fr) 1998-01-16
US20010047519A1 (en) 2001-11-29
WO1998002534A2 (fr) 1998-01-22
FR2750825B1 (fr) 2002-08-23
US6632977B2 (en) 2003-10-14

Similar Documents

Publication Publication Date Title
Inui Transgenic approach to the study of body weight regulation
ZA988139B (en) Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy.
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
EP1014881A4 (fr) Traitement d'affections neurodegeneratives par perfusion de facteurs de croissance nerveuse dans le cerveau
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
IL236404A0 (en) Doses for treatments using anti-erbb2 antibodies
WO2005099715A3 (fr) Traitement de pathologies ophtalmiques
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
WO1996023065A3 (fr) Inhibition de la neoformation de vaisseaux sanguins au moyen d'oligonucleotides specifiques de vegf
IL164882A0 (en) Selective nerve fiber stimulation for treating heart conditions
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
EP2298298A3 (fr) Utilisation des antagonistes de récepteur AT1 ou modulateur de récepteur AT2 pour le traitement des conditions ou maladies associées à l'augmentation des récepteurs AT1 ou AT2
ZA200104146B (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males.
WO2003089580A3 (fr) Modeles de cancer
GB2297691B (en) Method for improving breeding activity of boars by using feed for the breeding boars
WO1999048489A3 (fr) Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
WO1998002534A3 (fr) Animal transgenique dont l'expression des recepteurs aux opiaces est modifiee
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
EP1532250A4 (fr) Modele animal transgenique de fcyriia pour affection auto-immune
WO2004016751A3 (fr) Procedes de traitement de maladies neurodegeneratives
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques
AU4441101A (en) Biological material and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09214904

Country of ref document: US

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载